BIOHAVEN

Serial Number 87329452
Registration 6130617
700

Registration Progress

Application Filed
Feb 8, 2017
Under Examination
May 1, 2018
Approved for Publication
Mar 6, 2018
Published for Opposition
Mar 6, 2018
Registered
Aug 18, 2020

Trademark Image

BIOHAVEN

Basic Information

Serial Number
87329452
Registration Number
6130617
Filing Date
February 8, 2017
Registration Date
August 18, 2020
Published for Opposition
March 6, 2018
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 18, 2020
Registration
Registered
Classes
005

Rights Holder

BIOHAVEN THERAPEUTICS LTD.

99
Address
Ritter House, P.O. Box 173
Road Town, Tortola VG1110
VG

Ownership History

Biohaven Pharmaceutical Holding Company Limited

Original Applicant
99
New Haven, CT

Biohaven Pharmaceutical Holding Company Limited

Owner at Publication
99
New Haven, CT

Biohaven Pharmaceutical Holding Company Limited

Original Registrant
99
New Haven, CT

BIOHAVEN THERAPEUTICS LTD.

New Owner After Registration #1
99
Road Town, Tortola VG

Legal Representation

Attorney
Monica Riva Talley

USPTO Deadlines

Next Deadline
380 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-08-18)
Due Date
August 18, 2026
Grace Period Ends
February 18, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

50 events
Date Code Type Description Documents
Apr 17, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Apr 17, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 17, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Apr 17, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 17, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jan 11, 2023 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Jun 21, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jun 21, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 21, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 21, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jun 21, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 26, 2020 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Aug 18, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 16, 2020 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jul 15, 2020 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jun 25, 2020 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jun 23, 2020 IUAF S USE AMENDMENT FILED Loading...
Jun 23, 2020 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 14, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 13, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 13, 2020 EX4G S SOU EXTENSION 4 GRANTED Loading...
May 1, 2020 EXT4 S SOU EXTENSION 4 FILED Loading...
May 1, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 3, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 3, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 13, 2020 WOAR I TEAS WITHDRAWAL OF ATTORNEY RECEIVED Loading...
Jan 13, 2020 WOAG I WITHDRAWAL OF ATTORNEY GRANTED Loading...
Oct 25, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 23, 2019 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 23, 2019 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 23, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 23, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 23, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 26, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 24, 2019 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 24, 2019 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 24, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 12, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 10, 2018 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 10, 2018 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 10, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 1, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 6, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 6, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 14, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 1, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 30, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 30, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 26, 2018 ALIE A ASSIGNED TO LIE Loading...
Jan 16, 2018 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...

Detailed Classifications

Class 005
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
First Use Anywhere: Mar 13, 2020
First Use in Commerce: Mar 13, 2020

Classification

International Classes
005